Estados Unidos - inglés - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 2.5 mg - bromocriptine mesylate is indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. bromocriptine treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. in cases where adenectomy is elected, a course of bromocriptine therapy may be used to reduce the tumor mass prior to surgery. bromocriptine therapy is indicated in the treatment of acromegaly. bromocriptine therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately half of patients treated, although not usually to normal levels. since the effects of external pituitary radiation may not become maximal for several years, adjunctive therapy with bromocriptine offers p

Australia - inglés - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ergotamine tartrate; caffeine -

Australia - inglés - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - methysergide maleate; methysergide 1mg (as maleate) -

Australia - inglés - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - erythromycin ethyl succinate -

Australia - inglés - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - erythromycin ethyl succinate; erythromycin as ethylsuccinate -

Australia - inglés - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - dihydroergotamine mesylate - injection ampoule - 1mg/1ml - antimigraine preparations

Canadá - inglés - Health Canada

pfizer canada ulc - norgestrel - tablet - 0.075mg - norgestrel 0.075mg - contraceptives

Estados Unidos - inglés - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - pasireotide (unii: 98h1t17066) (pasireotide - unii:98h1t17066) - pasireotide 0.3 mg in 1 ml - signifor is indicated for the treatment of adult patients with cushing's disease for whom pituitary surgery is not an option or has not been curative. none. risk summary the limited data with signifor in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. in embryo-fetal development studies in rabbits, findings indicating developmental delay were observed with subcutaneous administration of pasireotide during organogenesis at doses less than the exposure in humans at the highest recommended dose; maternal toxicity was not observed at this dose (see data) . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. data animal data in embryo-fetal development studies in rats given 1, 5, and 10 mg/kg/day subcutaneously throughout organog

Estados Unidos - inglés - NLM (National Library of Medicine)

beaufour ipsen pharma sas - lanreotide acetate (unii: ieu56g3j9c) (lanreotide - unii:0g3de8943y) - 60 mg in 0.2 ml

Estados Unidos - inglés - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - sirolimus (unii: w36zg6ft64) (sirolimus - unii:w36zg6ft64) - sirolimus 0.5 mg - sirolimus tablets are indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. in patients at low- to moderate-immunologic risk, it is recommended that sirolimus tablets be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn 2 to 4 months after transplantation [see dosage and administration (2.2) ]. in patients at high-immunologic risk (defined as black recipients and/or repeat renal transplant recipients who lost a previous allograft for immunologic reason and/or patients with high panel-reactive antibodies [pra; peak pra level > 80%]), it is recommended that sirolimus tablets be used in combination with cyclosporine and corticosteroids for the first year following transplantation [see dosage and administration (2.3), clinical studies (14.3) ]. cyclosporine withdrawal has not been studied in patients with banff grade 3 acute rejection or vascular rejection prior to cyclosporine withdrawal, those who are